RIO DE JANEIRO, Oct. 8, 2025 /PRNewswire/ — Anbio Biotechnology participated in the 50th World Small Animal Veterinary Association Congress (WSAVA 2025), an international gathering that brought together veterinarians, researchers, and industry representatives from more than 100 countries. The event provided a platform for Anbio to present its veterinary diagnostic portfolio and exchange views with partners across global markets.
At WSAVA 2025, Anbio displayed five product lines:
Anbio Biotechnology Veterinary Diagnostic Portfolio
- Fluorescence Immunoassay (FIA)
- Dry Chemistry
- Molecular Diagnostics
- Colloidal Gold Rapid Tests
- Dry Chemiluminescence Immunoassay (CLIA)
The portfolio generated interest among veterinarians, distributors, and industry participants. The dry chemiluminescence and fluorescence immunoassay systems were noted for their precision and usability, while discussions with distributors reflected demand for accessible and accurate testing technologies in veterinary healthcare.
A key feature was Anbio’s molecular diagnostics platform, capable of producing multi-target real-time PCR results within 15 minutes. This function was highlighted as a practical option for the rapid detection of respiratory and infectious diseases in animals, where timely results are critical to clinical management. Delegates pointed to the relevance of such technologies in strengthening outbreak response and supporting routine diagnostic workflows.
The exhibition also provided opportunities for Anbio to engage with existing and potential partners, discuss distribution strategies, and consider future product rollouts. These exchanges underlined the increasing role of point-of-care diagnostics in veterinary practice and emphasized the importance of international collaboration in expanding access to diagnostic tools.
Looking ahead, Anbio will continue its global outreach. The company is scheduled to participate in the Wild West Vet Show 2025, taking place from October 15–18, 2025, in Reno, Nevada, USA. The exhibition will provide another opportunity to present its veterinary diagnostic portfolio and to interact with professionals from the North American market.
Anbio’s participation in WSAVA 2025 reflects its continuing efforts in both human and veterinary diagnostics. By advancing practical and reliable testing solutions, the company contributes to improving healthcare outcomes in diverse settings worldwide.
About Anbio Biotechnology
Anbio Biotechnology is a globally oriented in vitro diagnostics (IVD) company providing a broad range of solutions, including immunofluorescence, dry chemistry, chemiluminescence, molecular diagnostics, rapid testing and veterinary diagnostics. With operations across multiple regions, the company works to enhance the availability of reliable and timely diagnostics, supporting better decision-making in healthcare settings worldwide.
SOURCE Anbio Biotechnology
